Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

Crohn's disease sufferers experience slower cognitive response times, study shows

Crohn's disease sufferers experience slower cognitive response times, study shows

New research published in the UEG Journal1 has found that Crohn's disease sufferers experience slower response times than matched individuals that do not have the disease. [More]
Scientists discover novel African types of Salmonella linked to blood poisoning and death

Scientists discover novel African types of Salmonella linked to blood poisoning and death

The first global-scale genetic study of Salmonella Enteritidis bacteria, which is a major cause of blood poisoning and death in Africa and food poisoning in the Western World, has discovered that there are in fact three separate types. [More]
QUT molecular microbiologist developing new therapies to beat bacterial superbugs

QUT molecular microbiologist developing new therapies to beat bacterial superbugs

QUT molecular microbiologist Makrina Totsika is at the forefront of research to develop new therapies to beat multi-drug resistant bacteria. [More]
Study estimates health care costs of gastrointestinal illnesses in Switzerland

Study estimates health care costs of gastrointestinal illnesses in Switzerland

In Switzerland, between 300,000 and 700,000 patients per year visit a doctor due to acute diarrhoea. Until now, the financial burden on the Swiss health care system had been completely unclear. [More]
NPS MedicineWise urges child care centres to increase awareness around misuse of antibiotics in young children

NPS MedicineWise urges child care centres to increase awareness around misuse of antibiotics in young children

NPS MedicineWise has written to child care centres across Australia to enlist their support in responding to the growing problem of antibiotic resistance. Child care staff are well placed to help with education and increase awareness around the misuse of antibiotics in young children. [More]
Study sheds more light on how bacteria rapidly causes infectious diseases

Study sheds more light on how bacteria rapidly causes infectious diseases

Researchers at Umea University are first to discover that bacteria can multiply disease-inducing genes which are needed to rapidly cause infection. [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spider venom helps investigate pain signals experienced by irritable bowel syndrome patients

Spiders have helped researchers from Australia and the US discover a new target for irritable bowel syndrome pain. [More]
Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

Bacteriophage combinations show therapeutic potential in reducing C. difficile infections

A new University of Leicester study has confirmed the therapeutic potential of bacteriophage combinations to treat highly infectious bacteria C. difficile infections (CDI) while retaining a healthy gut. [More]
Global increase in sale of baby formula raises concerns about health of infants, mothers

Global increase in sale of baby formula raises concerns about health of infants, mothers

A new study from The Australian National University has found a global boom in the sale of infant and baby formula, especially in China and Southeast Asia, raising concerns about the health of millions of mothers and their babies. [More]
University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

University of Leicester researcher awarded grant to develop bacteriophages to target infant Shigella

A University of Leicester researcher has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world where it causes significant mortality. [More]
ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn. [More]
New data visualization platform identifies shortfalls in vaccine introduction and coverage

New data visualization platform identifies shortfalls in vaccine introduction and coverage

As the 69th World Health Assembly discusses progress on the Global Vaccine Action Plan, a new data visualization platform--from the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health--provides stark numbers on where shortfalls exist in vaccine introduction and coverage. [More]
New frozen faecal bank increases chances of curing a chronic health condition

New frozen faecal bank increases chances of curing a chronic health condition

A new frozen faecal bank that could save hundreds of lives and dramatically improve the quality of life of many more has been established at a Portsmouth hospital. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). [More]
AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme. [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Shigella dysenteriae pathogen probably originated in Europe, genetic study reveals

Shigella dysenteriae pathogen probably originated in Europe, genetic study reveals

The largest genetic study on the bacterium responsible for epidemic dysentery has revealed that the Shigella dysenteriae pathogen, which remains a real scourge in Africa and Asia, probably originated in Europe. [More]
Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. [More]
Advertisement